Sessions:
Suzhou
Thursday, September 3, 1pm – 5pm, Adocklab
Beijing
Tuesday, September 8, 1pm – 5pm, Yizhuang Biomedical Park
Summary
Join this interactive workshop to explore how Model-Informed Drug Development (MIDD) approaches can accelerate decision-making across the drug development lifecycle — from early discovery to market access.
Through expert-led sessions and real-world case studies, participants will learn how modeling and simulation approaches, including QSP, PBPK, and Pharmacometrics, can support data-driven decision-making, optimize development strategies, and generate quantitative insights throughout the drug development process.
Benefits of the event
- Understand the role of MIDD in accelerating drug development and improving decision-making
- Explore real-world applications of QSP, PBPK, and Pharmacometrics across different therapeutic modalities
- Learn how modeling approaches support complex modalities, special populations, DDIs, and dose optimization
- Gain insights into quantitative strategies for regulatory submissions and market access in global markets
- Discover software solutions that enable scalable modeling and simulation workflows
Register now
Caroline Mello
Portfolio Account Manager, CertaraCaroline is a Portfolio Account Manager at Certara specializing in modeling and simulation, including QSP, PBPK, and Pharmacometrics. She joined Certara via the acquisition of Applied BioMath, which focused on QSP for complex biologics. With a background in biochemistry and medicine, she is passionate about accelerating better therapeutics to patients through modeling and simulation.
Jia Ning, PhD
Senior PBPK ConsultantJia Ning, PhD joined Certara’s Simcyp group in 2019. She is primarily responsible for establishing PBPK models for drugs, predicting drug-drug interactions (DDI), and predicting pharmacokinetics (PK) in special populations.
She conducted research at Wageningen University in the Netherlands from 2015 to 2019. She excels in using PBPK models to predict hepatotoxicity of drugs and comparing differences between species and ethnic groups.
Ruijuan Zhu
Software Solution Consultant, CertaraRuijuan graduated from East China Normal University and is a visiting scholar at the University of Houston, USA. She is an expert in bioinformatics, with rich working experience in disease detection and drug development. Currently, she is responsible for the consulting service for drug development-related software at Certara and possesses profound knowledge and experience in utilizing Pinnacle 21 Enterprise (P21E) to ensure data compliance with CDISC standards.
You May Also Like
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
